We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Prothena's Partnership Strategy: Growth Driver or Limitation?
Read MoreHide Full Article
Key Takeaways
PRTA's partnerships with Roche, Novo Nordisk and Bristol Myers Squibb support its drug development pipeline.
PRTA received a $50M milestone payment for coramitug, with more payments possible as trials progress.
Prothena estimates $3B in milestone payments plus royalties from partnered programs.
Prothena Corporation (PRTA - Free Report) is focused on developing treatments for neurodegenerative and rare diseases. The company’s growth strategy relies significantly on partnerships with larger pharmaceutical companies to advance its drug candidates through clinical development and potentially toward commercialization. These collaborations provide financial support and access to development expertise, but they also mean that Prothena loses control over key programs.
Developing medicines requires substantial investment, and clinical trials can take several years to complete. Prothena’s partnerships help reduce the financial burden of advancing its pipeline independently. By working with established pharmaceutical companies, this clinical-stage biotechnology company can access additional research capabilities, clinical development expertise and commercial infrastructure. These arrangements may also provide milestone payments when specific development or regulatory goals are achieved, along with royalties if partnered medicines reach the market and generate sales. This approach enables the company to pursue multiple drug development opportunities without funding every development stage on its own.
However, the financial benefits depend on clinical progress, the terms of each agreement and the eventual commercial success of the partnered medicines.
RHHBY/PRTA Partnership Boosts Prasinezumab’s Development
One of Prothena’s key partnerships is with Roche (RHHBY - Free Report) , which is developing prasinezumab for the potential treatment of Parkinson’s disease. Roche initiated the phase III PARAISO study in late 2025, with primary completion expected in 2029. The partnership allows Prothena to benefit from Roche’s clinical development and commercialization capabilities without bearing the full cost of advancing the medicine independently.
Prasinezumab could become an important source of milestone payments and royalties for Prothena if it achieves regulatory approval and generates sales. However, the drug is still investigational and its commercial potential depends on the results of ongoing clinical studies. Any disappointing results or delays could affect the timing and value of future payments to Prothena.
NVO Partnership Creates Another Growth Opportunity
Prothena’s partnership with Novo Nordisk (NVO - Free Report) provides another potential source of long-term growth. Novo had earlier acquired Prothena’s clinical-stage antibody, Coramitug (formerly PRX004), a first-in-class amyloid depleter antibody for the treatment of ATTR amyloidosis with cardiomyopathy (ATTR-CM), a serious condition in which abnormal protein deposits can affect the heart.
Novo is studying the candidate under a late-stage CLEOPATTRA study for ATTR-CM. The study is expected to be completed by 2029. The ongoing open-label study evaluates the biodistribution of 89Zr-coramitug, and the assessment of coramitug’s ability to reduce TTR amyloid deposits in myocardial tissue using PET/CT imaging in patients with ATTR-CM is ongoing, with primary completion expected in 2027.
In March 2026, Prothena received a $50-million clinical milestone payment tied to the enrollment progress in the ongoing study of coramitug. This payment demonstrates how clinical progress in a partnered program can generate revenues for Prothena before a medicine reaches the market.
Coramitug could provide additional milestone payments and royalties if development progresses successfully. The program still faces clinical and regulatory risks and its ultimate commercial value will depend on the treatment’s safety, effectiveness and ability to compete in the ATTR-CM market.
Prothena’s collaboration with Bristol Myers Squibb (BMY - Free Report) adds another potential growth driver. The latter company is evaluating moponetug, also known as BMS-986446, in the phase II TargetTau-1 study for early Alzheimer's disease. The study was fully enrolled, with primary completion expected in the first half of 2027.
The partnership gives Prothena exposure to the potential Alzheimer's treatment market without requiring it to fund the entire development program independently. If the clinical results support further development, the program could generate milestone payments and future royalties.
Bristol Myers Squibb is also evaluating PRX019 for neurodegenerative diseases. The company in-licensed exclusive global rights to PRX019 in 2024. Prothena completed a phase I study evaluating the safety, tolerability, immunogenicity and pharmacokinetics of single-ascending and multiple-dose administration in healthy volunteers.
The company could receive a potential $55-million clinical milestone payment if Bristol Myers Squibb elects to advance the program, with a decision expected by the end of 2026.
Prothena's partnered programs could provide substantial financial benefits over time. In its February 2026 business update, the company estimated that these programs could generate $3 billion in aggregate future milestone payments, in addition to potential royalties.
Prothena's partnerships with the pharma bigwigs provide access to established drug development capabilities, and potential future milestone payments and royalties.
Clinical setbacks, changes in a partner's priorities or a decision to discontinue a program could reduce the company's future revenue opportunities.
View the Zacks #1 Rank List
Image: Bigstock
Prothena's Partnership Strategy: Growth Driver or Limitation?
Key Takeaways
Prothena Corporation (PRTA - Free Report) is focused on developing treatments for neurodegenerative and rare diseases. The company’s growth strategy relies significantly on partnerships with larger pharmaceutical companies to advance its drug candidates through clinical development and potentially toward commercialization. These collaborations provide financial support and access to development expertise, but they also mean that Prothena loses control over key programs.
Developing medicines requires substantial investment, and clinical trials can take several years to complete. Prothena’s partnerships help reduce the financial burden of advancing its pipeline independently. By working with established pharmaceutical companies, this clinical-stage biotechnology company can access additional research capabilities, clinical development expertise and commercial infrastructure. These arrangements may also provide milestone payments when specific development or regulatory goals are achieved, along with royalties if partnered medicines reach the market and generate sales. This approach enables the company to pursue multiple drug development opportunities without funding every development stage on its own.
However, the financial benefits depend on clinical progress, the terms of each agreement and the eventual commercial success of the partnered medicines.
RHHBY/PRTA Partnership Boosts Prasinezumab’s Development
One of Prothena’s key partnerships is with Roche (RHHBY - Free Report) , which is developing prasinezumab for the potential treatment of Parkinson’s disease. Roche initiated the phase III PARAISO study in late 2025, with primary completion expected in 2029. The partnership allows Prothena to benefit from Roche’s clinical development and commercialization capabilities without bearing the full cost of advancing the medicine independently.
Prasinezumab could become an important source of milestone payments and royalties for Prothena if it achieves regulatory approval and generates sales. However, the drug is still investigational and its commercial potential depends on the results of ongoing clinical studies. Any disappointing results or delays could affect the timing and value of future payments to Prothena.
NVO Partnership Creates Another Growth Opportunity
Prothena’s partnership with Novo Nordisk (NVO - Free Report) provides another potential source of long-term growth. Novo had earlier acquired Prothena’s clinical-stage antibody, Coramitug (formerly PRX004), a first-in-class amyloid depleter antibody for the treatment of ATTR amyloidosis with cardiomyopathy (ATTR-CM), a serious condition in which abnormal protein deposits can affect the heart.
Novo is studying the candidate under a late-stage CLEOPATTRA study for ATTR-CM. The study is expected to be completed by 2029. The ongoing open-label study evaluates the biodistribution of 89Zr-coramitug, and the assessment of coramitug’s ability to reduce TTR amyloid deposits in myocardial tissue using PET/CT imaging in patients with ATTR-CM is ongoing, with primary completion expected in 2027.
In March 2026, Prothena received a $50-million clinical milestone payment tied to the enrollment progress in the ongoing study of coramitug. This payment demonstrates how clinical progress in a partnered program can generate revenues for Prothena before a medicine reaches the market.
Coramitug could provide additional milestone payments and royalties if development progresses successfully. The program still faces clinical and regulatory risks and its ultimate commercial value will depend on the treatment’s safety, effectiveness and ability to compete in the ATTR-CM market.
Bristol Myers Squibb Partnership Expands PRTA’s Pipeline
Prothena’s collaboration with Bristol Myers Squibb (BMY - Free Report) adds another potential growth driver. The latter company is evaluating moponetug, also known as BMS-986446, in the phase II TargetTau-1 study for early Alzheimer's disease. The study was fully enrolled, with primary completion expected in the first half of 2027.
The partnership gives Prothena exposure to the potential Alzheimer's treatment market without requiring it to fund the entire development program independently. If the clinical results support further development, the program could generate milestone payments and future royalties.
Bristol Myers Squibb is also evaluating PRX019 for neurodegenerative diseases. The company in-licensed exclusive global rights to PRX019 in 2024. Prothena completed a phase I study evaluating the safety, tolerability, immunogenicity and pharmacokinetics of single-ascending and multiple-dose administration in healthy volunteers.
The company could receive a potential $55-million clinical milestone payment if Bristol Myers Squibb elects to advance the program, with a decision expected by the end of 2026.
Prothena's partnered programs could provide substantial financial benefits over time. In its February 2026 business update, the company estimated that these programs could generate $3 billion in aggregate future milestone payments, in addition to potential royalties.
Prothena's partnerships with the pharma bigwigs provide access to established drug development capabilities, and potential future milestone payments and royalties.
Clinical setbacks, changes in a partner's priorities or a decision to discontinue a program could reduce the company's future revenue opportunities.